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Abstract: The fractional flow reserve (FFR) is a simple, reliable, and reproducible physiologic index of lesion severity. In 
patients with intermediate stenosis, FFR0.75 can be used to safely defer percutaneous coronary intervention (PCI), and 
patients with FFR0.75 have a very low cardiac event rate. Coronary pressure measurement can determine which lesion 
should be treated with PCI in patients with tandem lesions, and PCI on the basis of FFR has been demonstrated to result in 
an acceptably low repeat PCI rate. FFR can identify patients with equivocal left main coronary artery disease who benefit 
from coronary bypass surgery. Coronary pressure measurement distinguishes patients with an abrupt pressure drop pattern 
from those with a gradual pressure drop pattern, and the former group of patients benefit from PCI. Coronary pressure 
measurement is clinically useful in evaluating sufficient recruitable coronary collateral blood flow for prevention of 
ischemia, which affects future cardiac events. FFR is useful for the prediction of restenosis after PCI. As an end-point of 
PCI, FFR 0.95 and 0.90 would be appropriate for coronary stenting and coronary angioplasty, respectively. In 
summary, if you encounter a coronary stenosis in doubt you should measure pressure rather than dilate it. 
Keywords:  Coronary pressure, fractional flow reserve, intermediate stenosis, tandem lesions, left main coronary artery, 
collateral blood flow. 
INTRODUCTION 
  Percutaneous coronary intervention (PCI) is often per-
formed without objective evidence of myocardial ischemia. 
Usually, a percent diameter stenosis of 50% as determined 
by quantitative coronary angiography is regarded to be sig-
nificant stenosis [1]. However, necropsy and intravascular 
ultrasound studies demonstrate that coronary lesions are 
often highly complex, exhibiting markedly distorted or 
eccentric luminal shapes [2-4]. This complex morphology 
impairs the ability of coronary angiography to accurately 
depict coronary anatomy. The problem of coronary artery 
remodeling and the validity of a normal reference segment 
further limit the ability of coronary angiography [5]. Thus, 
coronary angiography has considerable limitations in evalua-
ting coronary artery stenosis.  
  The fractional flow reserve (FFR) is a simple, reliable, 
and reproducible physiologic index of lesion severity [6]. 
Several studies demonstrate that the FFR is strongly related 
to inducible myocardial ischemia established by rigorous 
comparisons to different clinical stress testing modalities [6-
9]. Based on these considerations, FFR can be useful for 
evaluating coronary artery stenosis in various pathological 
conditions of coronary artery disease. 
  In this review we provide a short overview of the 
background of FFR and focus on its clinical application, both 
for diagnostic and therapeutic catheterization. 
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CONCEPT AND CHARACTERISTICS OF FFR 
  FFR is defined as maximum myocardial blood flow in 
the presence of a stenosis divided by the theoretical maxi-
mum blood flow in the same region in the absence of 
stenosis (Fig. 1). This index represents the fraction of normal 
maximum blood flow that is achievable despite the presence 
of the epicardial coronary stenosis [6, 7, 10]. 
FFR= Q
S / Q
N 
Q
S: maximum myocardial blood flow in the presence of a 
stenosis 
Q
N: normal maximum myocardial blood flow 
Q
N=(Pa-Pv)/R 
Pa: mean aortic pressure, Pv: mean central venous pressure 
R: myocardial resistance at maximum vasodilation 
Q
S=(Pd-Pv)/R 
Pd: hyperemic distal coronary pressure 
FFR=Pd-Pv/Pa-Pv 
  Because generally, central venous pressure is close to 
zero, this equation can be simplified to, 
FFR=Pd/Pa 
  The advantages of FFR are as follows; 1) it has an 
uniform normal value of 1.0 for every patient and every 
coronary artery, 2) its independent of changes in blood 
pressure, heart rate, and contractility, 3) it has a clear cut-off 
value of 0.75 to discriminate significant from non-significant 
stenosis, and 4) it needs no control coronary artery, and 5) it 
accounts for collateral blood flow. 
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  Regarding cut-off value of FFR, several studies have 
convincingly demonstrated that FFR of 0.75 accurately 
discriminates lesions with inducible reversible ischemia from  
those without inducible reversible ischemia [6-9]. An FFR 
<0.75 identified coronary stenosis in patients with inducible 
myocardial ischemia with high sensitivity (88%), specificity 
(100%), positive predictive value (100%), and overall 
accuracy (93%) [6]. 
TECHNICAL ASPECTS OF CORONARY PRESSURE 
MEASUREMENT 
  A pressure guide wire is zeroed, calibrated and advanced 
through the catheter into the coronary artery and positioned 
as distally as possible. Maximal hyperemia is then induced 
by intracoronary or intravenous continuous infusion of 
hyperemic agents (papaverine, adenosine, and adenosine 
triphosphate, Table 1). FFR is then calculated at the 
maximum hyperemia from the simultaneously recorded 
aortic (Pa) and distal coronary pressure (Pd) by the ratio of 
Pd/Pa. Thereafter the pullback pressure tracing from a point 
as distal as possible to the proximal part of the coronary 
artery under steady-state maximum hyperemia is obtained 
and recorded at paper speed of 5mm/sec. The pullback 
pressure tracing is performed twice to confirm the accuracy 
of FFR obtained. Continuous intravenous infusion is the best 
method to obtain stable maximum hyperemia and provides 
an excellent pull-back curve. Pullback curve at maximum 
 
Fig. (1). Concept of FFR. 
Q
S: maximum myocardial blood flow in the presence of a stenosis 
Q
N: normal maximum myocardial blood flow 
Pa: mean aortic pressure 
Pd: hyperemic distal coronary pressure 
Table 1.  Pharmacological Agents for Coronary Hyperemia 
 
  Papaverine  Adenosine  Adenosine Triphosphate 
Increase in CBF  4-6 times  4-6 times  4-6 times 
Half-life  60-90sec  <20sec  <20sec 
Plateau ic  30-60sec   5-10sec  5-10sec 
iv    <1-2min  <1-2min 
Dose      
ic RCA  10mg  30μg  30μg 
LCA  15-20mg  40-80μg  40-80μg 
iv    140-160μg/kg/min  140-160μg/kg/min 
Side Effect  QT prolongation  angina-like chest pain  angina-like chest pain 
  VT/Vf  BP decrease by 10-15%  BP decrease by 10-15%  
Abbreviations:  
BP; blood pressure, CBF; coronary blood flow, ic; intracoronary, iv; intravenous, LCA; left coronary artery, RCA; right coronary artery, VT; ventricular tachycardia, Vf; ventricular 
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hyperemia is the most accurate, most convincing, and most 
reliable way to study the functional status of every part of a 
coronary artery (Fig. 2) [11, 12]. 
FFR IN MICROVASCULAR DISEASE 
  FFR has one theoretical limitation, which is micro-
vascular disease. In patients with microvascular disease such 
as myocardial infarction, left ventricular hypertrophy, and 
diabetes mellitus, epicardial blood flow will not be as high as 
it would be in the case of normal microvascular function, 
which leads to overestimated FFR values. However, from a 
practical standpoint, FFR will still indicate to what extent the 
epicardial stenosis contributes to the limitation of the 
maximal perfusion in a given patient and to what extent the 
removal of the epicardial stenosis would lead to the 
improvement regardless of microvascular response. 
  In fact, there are several studies regarding the usefulness 
of FFR after myocardial infarction. De Bruyne et al. 
performed myocardial perfusion single photon emission 
scintigraphy (SPECT) and FFR measurement in 57 patients 
with myocardial infarction 6 days earlier [13]. The 
sensitivity and specificity of the 0.75 values of FFR to detect 
 
 
Fig. (2). Usefulness of pull back pressure tracing. A. A 65-year-old woman had a 72% stenosis in the distal segment of the right coronary 
artery and FFR was 0.57. B. After coronary stenting percent diameter stenosis improved to 8% but FFR improved only to 0.81. Pull back 
curve showed that there was no pressure gradient at the stented segment and pressure gradient was found at the proximal portion of the right 
coronary artery, to which we performed coronary angioplasty three months earlier. 326    Current Cardiology Reviews, 2009, Vol. 5, No. 4  Iwasaki and Kusachi 
flow maldistribution at SPECT imaging were 82% and 87%, 
respectively. Further, the concordance between the FFR and 
SPECT imaging was 85%. Another study examined 48 
patients 3.71.3 days after myocardial infarction [14]. The 
sensitivity, specificity, positive and negative predictive 
value, and concordance of FFR 0.75 for detecting true 
reversibility on SPECT were 88%, 93%, 88%, 93%, and 
92%, respectively. The optimal FFR value for discriminating 
inducible ischemia was 0.78. Therefore, FFR of the infarct-
related artery accurately identifies reversibility on non-
invasive imaging early after myocardial infarction.  
CLINICAL APPLICATION OF CORONARY 
PRESSURE MEASUREMENT (TABLE 2) 
1. Intermediate Stenosis 
 Fig.  (3) shows the relationship between percent diameter 
stenosis and FFR in our 417 patients with intermediate 
coronary stenosis, which is defined as percent diameter 
stenosis (% DS) between 40% and 70%. Our results show 
that considerable number of patients with intermediate 
stenosis had functionally non-significant stenosis. Our 
results also showed that coronary angiography could not 
discriminate between significant and non-significant stenosis 
in intermediate stenotic lesions. There was a large overlap of 
%DS between patients with normal FFR and those with 
abnormal FFR and the relationship between %DS and FFR 
in all patients was modest. Similar to our results, a study 
measured FFR in 83 patients with intermediate stenosis and 
compared the results with visual assessment and quantitative 
coronary angiography (QCA) of angiography. They found 
that neither visual assessment by experienced interventional 
cardiologist nor QCA could accurately predict the signi-
ficance of intermediate stenosis [15]. These results indicate 
that FFR is clinically useful to evaluate the severity of 
intermediate stenosis accurately. 
Table  2. Clinical Application of Coronary Pressure 
Measurement 
 
1.  Intermediate stenosis 
2.  Tandem lesions 
3.  Equivocal left main coronary artery disease 
4.  Diffuse coronary artery disease 
5.  Multivessel disease 
6.  Assessment of collateral blood flow  
7.  Determining end point of PCI 
 
  In patients with normal FFR the coronary event rate is 
lower with medical therapy as compared with coronary 
intervention. Eight previous studies, which included 24 to 
150 patients, reported a coronary event rate, defined as 
death, myocardial infarction, PCI, bypass surgery, of 8% to 
21% (mean 11%) during follow-up period of 11 to 29 (mean 
16.3) months, which means the annual event rate was 5.7% 
[16-23]. They also reported the annual hard event rate, 
defined as death and myocardial infarction, of 1% per year. 
This very low hard event rate is comparable with that of 
patients with normal stress myocardial perfusion imaging, 
which is reported to be 0.6-1.0% per year [24-26]. Recently 
Pijls  et al. reported the five-year follow-up data of the 
DEFER (Deferral versus Performance of PTCA in patients 
without Documented Ischemia) study [27]. Event-free 
survival was not different between patients with normal FFR 
and deferred PCI and those with normal FFR and performed 
PCI (80% and 73%, NS, respectively). Composite rate of 
cardiac death and myocardial infarction was 3.3% and 7.9%, 
respectively (NS). 
  Taken together, in patients with intermediate stenosis 
FFR 0.75 can be used to safely defer PCI, and that patients 
with FFR 0.75 have a very low cardiac event rate. 
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2. Tandem Lesions 
  In tandem lesions, evaluation of the severity of each 
lesion by coronary angiography is often difficult because of 
the complicated hydromechanics across tandem lesions. It is 
especially difficult to determine the severity of the tandem 
lesions when one or both lesions show intermediate stenosis 
[28]. Several noninvasive methods, such as stress myocardial 
perfusion imaging, are performed to evaluate the myocardial 
ischemia. However, these tests cannot determine which 
lesion of the two is responsible for reversible ischemia. 
Simple and reliable methods for evaluating the functional 
severity of the lesions are essential for decision making for 
PCI, especially in patients with equivocal tandem lesions. An 
animal study demonstrated that FFR of each lesion in a 
tandem lesion case could not be calculated using the 
equation for isolated stenosis applied to each lesion 
separately [29]. Another clinical study also indicated that the 
FFR of each stenosis would have been significantly 
overestimated without accounting for stenosis interaction 
[30].  
  To resolve this issue, Hirota et al. measured coronary 
pressure in 72 patients with tandem lesions [31]. For patients 
with FFR 0.75 across the tandem lesions they deferred PCI. 
When FFR was <0.75 across the tandem lesions, they perfor-
med PCI for the angiographically more severe stenosis. If 
FFR after PCI for the first lesion was 0.75, they deferred 
PCI for the second lesion. If FFR after PCI for the first 
lesion was <0.75, they performed PCI for the second lesion. 
As a result they deferred PCI for 26 patients (36.1%), 
performed PCI for one lesion in 19 patients (26.4%), and 
PCI for both lesions in 27 patients (37.5%). Among patients 
in whom PCI was deferred, only two patients (7.7%) 
required PCI during the follow-up period. This rate was not 
significantly different from that in the 46 patients who 
underwent PCI for one or two lesions (six patients, 13.0%). 
Thus this study showed that in patients with tandem lesions, 
FFR could clearly discriminate functionally significant 
stenosis and safely deferred PCI in those with normal FFR. 
3. Equivocal Left Main Coronary Artery Disease 
  Assessment of left main coronary artery (LMCA) disease 
by coronary angiography is often suboptimal [32, 33]. It is 
often difficult to make the decision of whether coronary 
revascularization for equivocal LMCA disease is required or 
not. Pathological studies demonstrated that atherosclerosis 
diffusely involves the coronary arteries and recent intra-
vascular ultrasound (IVUS) studies confirmed this finding in 
vivo [3, 34]. Intravascular ultrasound studies also found that 
coronary remodeling frequently occurs, which prevents the 
narrowing of the coronary arterial lumen through com-
pensatory enlargement of the coronary artery [5]. These 
findings indicate that a true reference segment cannot be 
identified by coronary angiography. In fact, Cameron et al. 
studied the reliability of angiographic assessment of LMCA 
stenosis [33]. They reviewed 106 coronary angiograms and 
found that there was only 41% to 59% agreement on the 
severity of the lesion among three groups of angiographers. 
Another study performed intravascular ultrasound study in 
60 patients [35]. While significant LMCA stenosis was 
present in 2 patients IVUS demonstrated plaques in 27 of 60 
LMCAs, six of them in patients with normal angiograms. 
When the LMCA lesion is immeasurably short, diffusely 
diseased, or obscured by overlapping vessels, determination 
of severity of the LMCA by angiography is especially 
difficult. Therefore, angiographic assessment is not reliable 
for the accurate evaluation of LMCA stenosis. 
  Furthermore, if an LMCA stenosis is not functionally 
significant, a bypass graft will be occluded and unnecessary 
bypass surgery will be performed. There is a study that 
followed 122 patients with moderate (50% diameter 
stenosis) LMCA stenosis for one year [36]. The lesion site 
minimum lumen diameter by quantitative coronary 
angiography correlated moderately with IVUS (r=0.364) and 
they found that one-year event rate was only 14%, and only 
four patients died. This study indicates that most patients 
with moderate LMCA stenosis do not benefit from CABG 
and that these patients may not have functionally significant 
LMCA stenosis.  
  If LMCA stenosis is not functionally significant and 
functionally significant coronary stenosis exists in the other 
part of coronary artery, PCI for this lesion should be the 
appropriate treatment. LMCA stenosis has been known to be 
frequently associated with coronary stenosis in the other part 
of coronary artery [37]. Non-invasive tests, such as myocar-
dial perfusion imaging, often fail to differentiate between 
ischemia caused by LMCA stenosis and that caused by 
coronary stenosis located in the other part of the coronary 
artery. 
  Most of these problems in evaluating LMCA stenosis can 
be solved by using coronary pressure measurement. There 
are several studies which selected treatment strategy based 
on FFR results in patients with equivocal LMCA disease. 
Suemaru  et al. studied 15 patients with equivocal LMCA 
stenosis [38]. Eight patients with FFR0.75 received medical 
therapy and seven patients with FFR <0.75 underwent 
CABG. During the follow-up period of 32.59.7 months, 
no adverse cardiac event occurred in patients with medical 
therapy. Two patients with CABG were hospitalized with 
congestive heart failure. Bech et al. measured FFR in 54 
patients with equivocal LMCA stenosis and assigned 24 
patients with FFR0.75 to medical treatment and 30 patients 
with FFR <0.75 to CABG [39]. Event-free survival at three 
years was not significantly different between the medical 
group and surgical group (76% vs. 83%, respectively). In 
medical group two patients underwent coronary angioplasty 
and three patients underwent CABG. These results clearly 
show that FFR can accurately evaluate the severity of 
LMCA stenosis. Careful follow-up of patients with medical 
therapy is very important. Rupture of coronary plaque in the 
LMCA followed by thrombus formation will likely result in 
a catastrophic event [40, 41]. Therefore, patients with medi-
cal therapy should be carefully observed with intensive 
medical therapy, including statin and ACE inhibitors. 
  As for coronary pressure measurement of LMCA 
stenosis, the position of the catheter is critical for the 
accurate assessment. The tip of the catheter should not be 
engaged in LMCA but rather should be slightly removed 
from the ostium of LMCA, which enables the precise 
measurement of the proximal coronary pressure of the 
LMCA stenosis. Then the pressure wire is gradually pulled 
back under fluoroscopy. Caution should be made to not 
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LMCA during gradual pull-back of pressure wire. These 
careful coronary pressure measurements provide precise FFR 
measurement across the LMCA lesion. 
  Taken together, coronary pressure measurement can 
identify patients with equivocal LMCA disease who benefit 
from coronary bypass surgery. 
4. Diffuse Coronary Artery Disease 
  Atherosclerosis usually involves the entire coronary 
artery tree to various extents [42, 43]. Diffuse atherosclerotic 
involvement of coronary arteries is one of the major factors 
affecting morbidity and mortality in patients with coronary 
artery disease [44, 45]. Thus detection and evaluation of the 
physiological significance of diffuse coronary artery disease 
have important therapeutic implications. 
  Coronary angiography again has some limitations for 
evaluating diffuse stenosis of the coronary arteries [28, 46, 
47]. Current quantitative coronary angiographic measure-
ment of percent diameter stenosis does not account for the 
true normal coronary arterial size because only the lumen of 
the reference segment is used for comparison [47]. The true 
size of an artery is often obscured because of coronary 
arterial remodeling [5]. Thus interpretations of coronary 
angiography severely underestimate mild or diffuse coronary 
atherosclerosis and overestimate the severity of stenosis with 
 
 
Fig. (4). Abrupt pressure drop pattern. 
Pull back pressure tracing in a patient with an abrupt pressure drop pattern before (A) and after (B) treatment with PCI. An abrupt drop of 
coronary pressure was observed and FFR was 0.47. Six months after PCI, the pressure difference was reduced and FFR improved to 0.79. Coronary Pressure Measurement  Current Cardiology Reviews, 2009, Vol. 5, No. 4    329 
>50% diameter narrowing [44, 48]. Many studies have 
shown that visual interpretation of coronary angiography 
severely underestimates mild or diffuse coronary artery 
disease [28, 46, 47]. Seiler et al. showed that in patients with 
even mild segmental stenosis, the luminal diameters of 
coronary arteries over a broad region are 30-50% smaller 
than they should be for the regional mass served [49, 50]. 
Thus, coronary angiography is not a reliable method to 
determine the severity of diffuse coronary artery disease. 
  The frequency and fluid dynamic severity of diffuse 
coronary artery narrowing in patients with coronary artery 
disease have not been previously described. Coronary flow 
reserve measured distally by intracoronary Doppler or 
pressure guide wires is lower than that measured proximally 
and correlates better with stress perfusion defects than with 
proximal measurements of coronary flow reserve [7, 51, 52]. 
A study examined 1001 patients with documented coronary 
artery disease by positron emission tomography [53]. The 
study showed that 43% of patients with or without segmental 
perfusion defects demonstrated a graded, longitudinal, base-
to-apex myocardial perfusion gradient, indicating dynami-
cally significant diffuse coronary artery disease. 
  Pijls reported two patients with two different patterns   
of coronary pullback pressure in angiographically diffuse 
coronary artery stenosis [54]. One patient showed a local 
pressure drop pattern and the other showed a gradual 
pressure drop pattern. We measured coronary pressure of the 
left anterior descending coronary artery in 83 patients with 
diffuse coronary artery disease. The abrupt pressure drop 
pattern was observed in 47 patients (57%), while the remain-
ing 36 patients (43%) showed the gradual pressure drop 
pattern (Figs. 4,  5). Patients with an abrupt pressure drop 
pattern would benefit from localized therapy, which means 
PCI. CABG for gradual pressure drop lesions may provide 
some positive effects through the elevation of coronary 
perfusion pressure to the peripheral coronary artery tree. 
  Taken together, coronary pressure measurement can 
distinguish patients with an abrupt pressure drop pattern 
from those with a gradual pressure drop pattern, and the 
former group of patients would benefit from PCI. 
5. Multivessel Disease 
  In multivessel disease accurate lesion selection for PCI is 
important. Some noninvasive studies demonstrated that 
SPECT fails to correctly indicate all ischemic area in 90% of 
patients. In one third of such patients, no perfusion defect 
was present because of balanced ischemia [55]. 
  There is a study that measured FFR in 102 patients with 
multivessel disease, in whom PCI of at least two vessels was 
contemplated [56]. In all of them at least one vessel was 
treated by PCI, whereas at least one other vessel was 
deferred based on an FFR >0.75. No death occurred during 
the follow-up. The rate of major adverse cardiac event was 
not significantly different between treated and deferred 
arteries (p=0.64). Similarly, another study examined 137 
patients with multivessel disease [57]. In 57 patients FFR 
measurement of all vessels were performed and PCI of 
stenoses with FFR <0.75 was performed (FFR-PCI group). 
The remaining 80 patients underwent PCI by visual 
estimation of the stenoses (conventional PCI group). The 
average number of vessels per patient that underwent PCI 
was greater in the conventional PCI group than in the FFR-
PCI group (2.270.50  vs. 1.120.30 vessels, p<0.001). 
The 30-month event-free survival rate was significantly 
higher in the FFR-PCI group than in the conventional PCI 
group (89% vs. 59%, p<0.01). Thus, these studies suggest 
that in patients with multivessel disease, PCI of hemodyna-
mically non-significant stensoses can be safely deferred, and 
FFR measurement is a cost-effective method. Currently the 
Fractional Flow Reserve versus Angiography for Multivessel 
Evaluation (FAME) study is underway to examine the role 
of measuring FFR in patients undergoing multivessel PCI 
[58]. 
 
Fig. (5). Gradual pressure drop pattern. 
Pull back pressure tracing in a patients with a gradual pressure drop pattern. A gradual drop of coronary pressure was observed and FFR was 
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6. Collateral Blood Flow 
  Collateral circulation potentially offers an important 
alternative source of blood supply when the original vessel 
fails to provide sufficient blood [59, 60]. There have been 
controversial results regarding the cardioprotective effects of 
angiographically present collaterals. Much of the argument is 
likely attributed to the blunt method of gauging human 
coronary collaterals by coronary angiography. Coronary 
angiography has been reported to be not a reliable method to 
evaluate collateral blood flow [28]. Recent studies which 
directly compare the angiographic scoring system and 
quantitative functional measures of collateral supply, such as 
pressure- or Doppler-derived collateral flow indexes, found 
only a very weak correlation, or none at all [61-63]. In 
contrast experimental and clinical studies, which measured 
coronary wedge pressure during coronary occlusion and 
directly determined collateral blood flow, demonstrated the 
close relationship between coronary wedge pressure and 
collateral flow [61, 64, 65]. Furthermore, a close relation 
between coronary wedge pressure and myocardial perfusion 
by positron emission tomography and 
99mTc-sestamibi has 
been reported [66, 67]. These studies support that the 
coronary wedge pressure measured by a pressure guide wire 
is reliable and valid for the assessment of coronary collateral 
flow. Angiographic collateral quantitation has been perfor-
med to look for spontaneously visible instead of recruitable 
collaterals, the latter of which appear in response to 
occlusion of the collateral receiving vessel and reflect 
collateral supply more comprehensively than the former. 
  During balloon inflation, coronary wedge pressure (Pw) 
is continuously recorded with the pressure guide wire. Aortic 
pressure (Pa) is also recorded through the guiding catheter. 
Recruitable collateral blood flow (Qc/Q
N) is expressed as a 
fraction of normal maximum myocardial perfusion (Q
N): 
Qc/Q
N = (Pw-Pv)/(Pa-Pv), where Pv is central venous 
pressure.  
  Regarding the cutoff value that indicates sufficient 
collateral blood flow to prevent ischemia during coronary 
occlusion, a Qc/Q
N value of 0.20 to 0.30 has been reported 
by different methods [68, 69]. A physiological study 
demonstrated that one-quarter of the resting coronary flow 
meets the basal metabolic requirements for maintaining the 
metabolic integrity of the cardiac cells [70]. 
 Kamikawa  et al. measured coronary pressure during 
coronary occlusion with PCI in 119 patients with left 
anterior descending coronary artery stenosis [71]. A 
significant relationship between Qc/Q
N and maximum ST 
elevation was observed (r=-0.455, p<0.0001). Also Qc/Q
N 
was significantly correlated with the sum of the maximum 
ST elevation in leads V2-V4 (r=-0.477, p<0.0001). Thus, 
recruitable collateral blood flow determined by coronary 
pressure measurement correlated with myocardial ischemia 
estimated by electrocardiographic changes during coronary 
occlusion. 
  Recent studies demonstrate a beneficial impact of well-
developed collaterals on the occurrence of future major 
cardiac ischemic events. Billinger et al. studied 403 patients 
with stable coronary artery disease undergoing coronary 
angioplasty and calculated collateral flow index using 
intracoronary pressure or Doppler guidewires [72]. During 
follow-up period of 9456 weeks, major cardiac ischemic 
event rate was 2.2% in patients with well developed 
collateral blood flow compared with 9.0% in those with 
poorly developed collateral blood flow (p=0.01). Similarly, 
another study reported the beneficial effect of recruitable 
collaterals [73]. They measured coronary pressure in 739 
patients with stable coronary artery disease and calculated 
collateral flow index. Cumulative 10-year survival rate   
was 89% and 71% in patients with well-grown collateral 
group and poorly developed collateral group, respectively 
(p=0.0395). Thus, well-functioning coronary collateral circu-
lation saves lives in patients with stable coronary artery 
disease and accurate determination of collateral blood flow is 
important. 
  Taken together, coronary pressure measurement with use 
of cut off value around 0.30 is clinically useful in evaluating 
sufficient recruitable coronary collateral blood flow for 
prevention of ischemia, which affects future cardiac events. 
  In summary, if you encounter a coronary stenosis in 
doubt you should measure pressure rather than dilate it. 
7. End Point of PCI 
  Restenosis is a major limitation of PCI and even drug-
eluting stents do not eliminate this phenomenon. The reste-
nosis rate after coronary angioplasty is reported to be 30-
50% and that of coronary stenting by bare-metal stent is 20-
30%. A cardiac event occurs in 30% of patients after coro-
nary angioplasty and 15% after coronary stenting [74-77]. 
Recent drug-eluting stent studies show a very low restenosis 
rate. However the restenosis rate is reported to be 5-10% and 
cardiac event occurs in 10% of patients [78, 79]. Many 
studies demonstrate that coronary angiography, including 
quantitative coronary angiography, is poor predictor of 
restenosis [80, 81]. Therefore, alternative approaches to 
assess lumen enlargement, such as intravascular ultrasound, 
have been advocated to better identify patients in whom 
restenosis is less likely [82, 83]. 
  Usefulness of FFR for predicting clinical outcomes after 
coronary angioplasty has been reported [19]. A study 
examined 60 patients who underwent successful coronary 
angioplasty using FFR. Patients with FFR 0.90 and %DS 
35% (optimal group) showed better event-free survival rate 
compared with those FFR <0.90 and/or %DS >35% (subop-
timal group, 925% vs. 728% at six months, respectively, 
p=0.047). Repeat PTCA rate was 3.8% in the optimal group 
and 15.6% in the suboptimal group at six months after 
PTCA, which was not significantly different. Thus, in 
patients with a residual %DS 35% and FFR 0.90, clinical 
outcome up to 2 years was excellent. 
 Pijls  et al. reported the usefulness of FFR to predict 
adverse events after coronary stenting [84]. They reported 
the adverse cardiac events of 750 patients who underwent 
coronary stenting. A significant inverse correlation was 
found between final FFR and occurrence of adverse events 
during follow-up. Also the correlation was significant for 
repeat target vessel revascularization. At 6 months follow-
up, adverse cardiac rate was 4.9% and 6.2% in patients   
with FFR 0.96-1.00 and 0.91-0.95, respectively (p<0.001). 
According to multivariate analysis, FFR after coronary 
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months. Another study enrolled 119 patients who underwent 
coronary stent implantation and studied the predictors of 
cardiac events [85]. They found that final FFR <0.95 and 
reduced left ventricular function remained as significant 
independent predictors in a multivariate analysis.  
 Similarly  Fearon  et al. measured FFR and made a 
comparison with intravascular ultrasound findings in 84 
patients with stent implantation. They found an optimal FFR 
cutoff point of 0.96 by receiver operator characteristic 
analysis [86]. There is also a study that compared QCA, 
IVUS, and FFR to assess optimal stent deployment in 30 
patients who underwent coil-stent implantation [87]. The 
study found that 91% of FFR and IVUS findings yielded 
concordant results but QCA showed a low concordance rate 
with FFR and IVUS. As for slotted-tube stents substantial 
concordance between FFR and IVUS findings has been 
reported [88]. 
  Taken together, FFR can be used as a good indicator of 
optimal PCI results. As an end point of PCI, FFR 0.90 and 
0.95 would be appropriate for coronary angioplasty and 
coronary stenting, respectively. 
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